Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
174.80-0.82 (-0.47%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close175.62
Bid174.55 x 100
Ask175.10 x 100
Day's Range174.61 - 176.85
52wk Range130.09 - 176.85
1y Target EstN/A
Market Cap130.81B
P/E Ratio (ttm)17.89
Avg Vol (3m)2,864,382
Dividend & Yield4.00 (2.29%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal2 days ago

    FDA Approves Amgen's Biosimilar Version of Humira

    U.S. regulators approved Amgen Inc.’s copy of the AbbVie Inc.’s anti-inflammatory treatment, Humira, which was the second-biggest selling drug in 2015.

  • Associated Press2 days ago

    FDA approves lower-cost alternative to biotech drug Humira

    Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory ...

  • PR Newswire2 days ago

    FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

    THOUSAND OAKS, Calif., Sept. 23, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.